Aytu BioPharma
AYTU | NASDAQ
$1.82
+$0.04 (+2.25%)
At close: Nov 16, 2026, 4:00 PM ET
$2.62
+$0.80 (+43.97%)
After-hours:
Nov 16, 2026, 7:59 PM ET
Aytu BioPharma Company Profile
Company profile explainedCompany Profile
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
Key Executives
| Name | Position |
|---|---|
| Joshua R. Disbrow | Chief Executive Officer & Director |
| Ryan J. Selhorn | Chief Financial Officer, Corporate Secretary & Treasurer |
| Gerwin Westfield | Senior Vice President of Scientific Affairs |
| Greg Pyszczymuka | Chief Commercial Officer |
| Jarrett T. Disbrow | Chief Business Officer |
| Margaret Cabano | Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | DEFA14A | Filing |
| Oct 22, 2026 | DEF 14A | Filing |
| Sep 22, 2026 | 10-K | Annual Report |
| Sep 22, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
Aytu BioPharma
| Country | United States |
| IPO Date | Sep 25, 2008 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Joshua R. Disbrow |
Contact Details
7900 East Union Avenue, Suite 920 Denver,
Colorado 80237 United States
Stock Details
| Ticker Symbol | AYTU |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001385818 |
| CUSIP Number | 054754858 |
| ISIN Number | US0547548588 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove AYTU